Oncomed Pharmaceuticals (NASDAQ:OMED) Director Jonathan D. Root sold 13,052 shares of the stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $21.05, for a total value of $274,744.60. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) in last trading activity moved up 2.68% to close at $21.48. Company weekly performance is 1.42% while its quarterly performance stands at 11.64%. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) is -49.27% away from its 52 week high.
Analysts at TheStreet upgraded shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) from a “sell” rating to a “hold” rating in a research note on Friday. On last trading day Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) moved up 3.58% to close at $7.24. Its volatility for the week is 4.38% while volatility for the month is 4.79%. PGNX’s sales growth for past 5 years was -34.90% and its EPS growth for past 5 years was 12.50%. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) monthly performance is 2.26%.
Delta Apparel, Inc. (NYSEMKT:DLA) on 4 December reported net sales for the fiscal year ended September 27, 2014, of $452.9 million, versus $483.0 million in the prior twelve months. The Company’s net income, adjusted for the $4.0 million pre-tax impact of strategic initiatives, was $1.5 million, or $0.19 per diluted share, compared with net income in the prior year of $6.2 million, or $0.74 per diluted share. On last trading day Delta Apparel Inc. (NYSEMKT:DLA) moved up 1.56% to close at $10.40. Its volatility for the week is 4.01% while volatility for the month is 2.65%. DLA’s sales growth for past 5 years was 5.00% and its EPS growth for past 5 years was -16.60%. Delta Apparel Inc. (NYSEMKT:DLA) monthly performance is -1.14%.
MVC Capital, Inc. (NYSE:MVC) will begin trading ex-dividend on December 29, 2014. A cash dividend payment of $0.453125 per share is scheduled to be paid on January 15, 2015. MVC Capital, Inc. (NYSE:MVC) has 4.70% insider ownership while its institutional ownership stands at 56.90%. In last trading activity company’s stock closed at $10.04.
On December 5, 2014, the Board of Directors of GenVec, Inc. (NASDAQ:GNVC) designated James V. Lambert, 50, to serve as the Company’s Principal Financial Officer and Principal Accounting Officer, effective immediately. Mr. Lambert will continue in his role as Senior Director, Accounting and Finance, a position he has held since 2010, prior to which he served in a variety of positions at the Company since October 2006, including Senior Controller. He will also now serve as Corporate Controller and Treasurer.On Friday shares of GenVec, Inc. (NASDAQ:GNVC) closed at $2.11. Company’s sales growth for last 5 years was -24.50% and EPS growth for next 5 years is recorded as 35.00%.